CN103211150A - Polypeptide food containing active earthworm protein - Google Patents
Polypeptide food containing active earthworm protein Download PDFInfo
- Publication number
- CN103211150A CN103211150A CN2013101841118A CN201310184111A CN103211150A CN 103211150 A CN103211150 A CN 103211150A CN 2013101841118 A CN2013101841118 A CN 2013101841118A CN 201310184111 A CN201310184111 A CN 201310184111A CN 103211150 A CN103211150 A CN 103211150A
- Authority
- CN
- China
- Prior art keywords
- parts
- polypeptide
- protein
- food
- soybean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 99
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 94
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 72
- 235000013305 food Nutrition 0.000 title claims abstract description 57
- 241000361919 Metaphire sieboldi Species 0.000 title claims abstract description 21
- 235000018102 proteins Nutrition 0.000 claims abstract description 71
- 241000209140 Triticum Species 0.000 claims abstract description 39
- 235000021307 Triticum Nutrition 0.000 claims abstract description 39
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 36
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 36
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 32
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 32
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 31
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims abstract description 31
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 30
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 30
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000000787 lecithin Substances 0.000 claims abstract description 8
- 235000010445 lecithin Nutrition 0.000 claims abstract description 8
- 244000068988 Glycine max Species 0.000 claims abstract description 6
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 6
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 31
- 240000002900 Arthrospira platensis Species 0.000 claims description 31
- 235000010439 isomalt Nutrition 0.000 claims description 31
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 29
- 239000000905 isomalt Substances 0.000 claims description 27
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 27
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 27
- 239000008108 microcrystalline cellulose Substances 0.000 abstract description 26
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract description 26
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract description 4
- 229940067606 lecithin Drugs 0.000 abstract description 4
- 230000000050 nutritive effect Effects 0.000 abstract description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 241001474374 Blennius Species 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 27
- 229940083466 soybean lecithin Drugs 0.000 description 27
- 229940082787 spirulina Drugs 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 238000007796 conventional method Methods 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 241000186000 Bifidobacterium Species 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 108010068370 Glutens Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 235000008098 Oxalis acetosella Nutrition 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 241001119526 Paullinia Species 0.000 description 2
- 235000010240 Paullinia pinnata Nutrition 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229940001501 fibrinolysin Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- -1 digestive ferment Proteins 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000003093 somatogenic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a polypeptide food containing an active earthworm protein. The polypeptide food comprises the following raw materials in parts by weight: 20-35 parts of active earthworm protein, 10-25 parts of wheat oligopeptide, 10-15 parts of soybean protein isolate, 10-25 parts of kudzuvine root powder, 10-15 parts of soybean protein isolate, 10-15 parts of spiral seaweed, 5-10 parts of soyabean lecithin, 5-10 parts of palatinitol, 2-5 parts of microcrystalline cellulose and 1-3 parts of magnesium stearate. The product is easily absorbed by the human body and has high nutritive value and has the effect of preventing and treating diseases; and moreover, the application range is wide, and the variety of domestic and overseas polypeptide foods is enriched.
Description
Technical field
The invention belongs to food technology field, specifically relate to a kind of polypeptide food, is the animals and plants polypeptide food that major ingredient is prepared from active ground dragon protein and wheat oligopeptide particularly.
Background technology
Polypeptide is that a-amino acid links together with peptide chain and the compound that forms, and it also is the intermediate product of proteolysis.Its molecular weight is lower than 10000 dalton, can and not precipitated by trichloroacetic acid and ammonium sulfate through pellicle.
Past, people thought always, and human body is mainly with amino acid whose form attract proteins.In recent years, international scientific circle discovers, protein is after the hydrolysis of alimentary canal enzymatic, and mainly the form with little peptide is absorbed, and is easier than complete free amino acid, absorbed by body sooner.
Scientific experimentation proves that the mechanism of absorption of polypeptide has ten big characteristics:
1, need not digest, directly absorb.Usually, polypeptide is that human body self is synthetic, and human body carries out enzymatic hydrolysis with the protein of being eaten, and protein is transformed into amino acid earlier, and synthetic then peptide finally absorbs by small intestine, then by human body cell, tissue, organ and blood circulation.And there is layer protecting film on artificial synthetic polypeptide surface; can not be subjected to short enzyme, pepsin, pancreatin, amylase, digestive ferment and the hydrolysis of acid-base material secondary of human body, it directly enters small intestine with complete form, is absorbed by small intestine; enter the human recycle system, the performance biological function.
2, absorb fast.Oral agents is as injection, the polypeptide that prosthesis is synthetic outward, the oral human body that enters, can pass people's oral cavity, stomach apace, directly enter small intestine, by little intestinal absorption, finally enter the blood of human body circulatory system, organ and cell tissue, bring into play its physiological action and biological function rapidly.
When 3, absorbing, the polypeptide body can be not destroyed.The polypeptide body self has layer protecting film; when the people takes; can not be subjected to the infringement or the secondary hydrolysis of the acid-base material in short enzyme, pancreatin, amylase, digestive ferment, pepsin and the digestive system in the human body, polypeptide is to be absorbed by the body and to utilize with complete form.
4, polypeptide has 100% characteristics that are absorbed by the body.After the absorption, do not have excreta, and be all to be absorbed by the body and to utilize.
5, polypeptide has the advantages that initiatively be absorbed by the body.For because of digestive system defective, obstacle, damage, and can not absorb nutrition person, polypeptide has the advantages that initiatively allow absorption of human body or force allow absorption of human body.This is poor for those digestion powers, and nutritional deficiency is in poor health, and the valetudinarian has great significance.
6, polypeptide has the advantages that preferentially be absorbed by the body.The usual nutriment of eating of people, on absorbing, in the competition of polypeptide, polypeptide has the characteristics of preferential absorption.The characteristics of this and its active absorption are undivided.
7, human body does not have and need expend body energy the absorption of polypeptide, need not increase alimentary canal, particularly the gastrointestinal function burden.Polypeptide self has extremely strong activity and energy, its active absorption, forces absorption, be exactly self activity and energy in action.Therefore, it is not that the energy that human body will expend self goes to absorb it when being absorbed by the body, but polypeptide with self energy by absorption of human body.In view of this, its this distinguishing feature is to the infant of digestive system undeveloped mature, the elderly that digestive system is begun to degenerate and be badly in need of nitrogenous source because of overexercise, and sportsman, the physical labourer that can not increase the gastrointestinal function burden have significance.
8, the carrier function that shows in human body of polypeptide can be with the nutriment that the mediocrity ate, and particularly calcium etc. adsorbs, pastes, is loaded on the body human body beneficial's trace element.
9, polypeptide can play the transportation instrument in human body.After can being adsorbed on the usual various nutriments of eating of people on the body, delivery be transported to each cell of human body, organ, tissue then, is absorbed by the body together and utilizes with body, brings into play different separately functions.Here it is, and present people in the world its objective is the reason of polypeptide raw material midbody as medicine and food formula will strengthen drug effect, strengthen absorptivity.
10, after polypeptide is absorbed by the body, can in human body, play courier's effect.It transmits information as neurotransmitter, and commander is neural, brings into play self-acting, safeguards the team spirit and the group effect of human nerve, makes human body become flexible more, sensitive, wise.In a word, the mechanism of absorption of the mechanism of absorption of polypeptide and other various materials differs widely.
Needs replenish though along with the level of consumption rises, after eating patterns were adjusted, the essential amino acid that people are taken in food did not lack, and some peptide lacks easily, to improve " inferior health " state of modern.Therefore expert advice at somatogenic need, after the basic nutrition that has satisfied human body is taken in, suitably replenishes polypeptide nutrition, benefits for healthy and rehabilitation.The polypeptide food of Xiao Shouing is single animal polypeptide such as protein peptides or plant polypeptide such as soya-bean polypeptides etc. mostly in the market, and its kind is simple, and effect is limited, does not bring into play the due effect of polypeptide fully; " a kind of compound silkworm chrysalis polypeptide functional food " (patent No.: the 200610032923.0) prescription that provides a kind of animal polypeptide and plant polypeptide to form, its silkworm chrysalis polypeptide that adopts be not health ministry approval be food be again the article or the new resource food of medicine, can not use as bread and cheese; The prescription that " a kind of complex polypeptide nutrition healthy food and production method thereof " (patent No.: ZL 200710050356.6) provides a kind of animal polypeptide and plant polypeptide to form, but the Acid polypeptide in its prescription be not health ministry approval be food be again the article or the new resource food of medicine, can not use as bread and cheese; Simultaneously, contain glucose and maltodextrin in this food, blood sugar height or diabetic population should not eat more, influence its range of application.
Summary of the invention
The purpose of this invention is to provide a kind of polypeptide food that contains active ground dragon protein, its used primary raw material-ground dragon protein and wheat oligopeptide all belong to new resource food, simultaneously auxiliary material also adopts the health ministry approval be food be again the composition of medicine or new resource food.Polypeptide food of the present invention has wide range of applications, the equal edibles of special population such as blood sugar height, high blood pressure or diabetes.It not only is of high nutritive value, and has the effect of certain disease preventing and treating, has enriched domestic and international polypeptide food kind.
The polypeptide food that contains active ground dragon protein of the present invention, it comprises the raw material of following parts by weight:
Active earthworm protein 20～35 parts
10～25 parts of wheat oligopeptides
10～25 parts of kudzu-vine root powder
10～15 parts of soybean protein isolates
10～15 parts of spirulinas
5～10 parts of soybean lecithins
5～10 parts of isomalts
2～5 parts of microcrystalline celluloses
1～3 part of dolomol.
Further preferred, it comprises the raw material of following parts by weight:
Active earthworm protein 25～35 parts
20～25 parts of wheat oligopeptides
10～15 parts of kudzu-vine root powder
10～13 parts of soybean protein isolates
10～15 parts of spirulinas
5～10 parts of soybean lecithins
5～10 parts of isomalts
2～5 parts of microcrystalline celluloses
1～3 part of dolomol.
The effect of above-mentioned each key component and effect:
Described active earthworm protein extraction from earthworm (the Latin literary fame:
Pheretima), it can extract by prior art and obtain, and it belongs to the new resource food for the health ministry approval.Active ground dragon protein contains multiple compositions such as clostridiopetidase A, fibrinolysin and Lumbrokinase, and its molecular weight belongs to the short chain small-molecule substance 1000～10000 dalton.It has following several characteristic:
1, the fresh and old thrombus of dissolving.The fibrinolysin, activator of plasminogen and the clostridiopetidase A that are rich in the active ground dragon protein can not only dissolve fresh thrombus, can also dissolve the old thrombus, and to the prevention of cardiovascular and cerebrovascular diseases, effective function is played in the rehabilitation of apoplexy sequelae.
2, improve systemic microcirculation: active ground dragon protein can dissolve the little bolt in the capilary, allows the capilary of sclerosis recover elasticity, thereby removes microvascular obstruction, torsional deformation situation, improves microcirculation.
3, softening blood vessel, stabilize plaque: fibrinoclase and other active material that active ground dragon protein is contained, can dissolve fibrin net on the atherosis tube wall, promote synthesizing of vascular endothelial cell DNA, the vascular wall of damage is repaired, recover blood vessel elasticity, change to a certain extent and stop the arteriosclerotic course of disease.
4, set up offshoot circulation, improve the cardiac and cerebral blood-supply oxygen supply: active ground dragon protein is the fertile absorber in the earthworm, can activate the differentiation characteristic of vascular endothelial cell, promotes capilary regeneration, opens up new blood access for the heart and brain tissues of focal zone, sets up offshoot circulation.
5, bidirectional modulation blood pressure:, can reduce the blood flow peripheral resistance, thereby have the effect of two-way stabilizing blood pressure by recovering blood vessel elasticity, thrombus, improving microcirculation.
6, reducing blood glues: active ground dragon protein can reduce erythrocyte and leukocytic adhesion, thereby reduces blood viscosity.
Active ground dragon protein can effectively be prevented and treated diseases such as disease such as the cerebrovascular and heart and hypertension, high fat of blood and dyslipidemia, diabetes.Active ground of the present invention dragon protein can adopt existing technology to prepare, and also can buy from the market to obtain.
Described wheat oligopeptide (wheat oligopeptides) is the new resource food of health ministry approval, it is to be raw material with the wheat gluten flour, through size mixing, technology such as protease hydrolyzed, separation, filtration, spray-drying makes, its protein content is stabilized in more than 90%, contain 19 seed amino acids, simultaneously its relative molecular weight quality less than 1000 daltonian protein hydrolysates be the polypeptide proportion greater than 75%, it is absorbed by the body than protein is easier, and has:
1, suppress cholesterol rising and the effect of promotion insulin secretion: its functional mass is a compound sugar amino acid, can be used for mediator's blood sugar, improves diabetic symptom.The effect of the nervous plain enzyme of energy line artery, thereby hypotensive activity is arranged.
2, the wheat oligopeptide contains high glutamine, can effectively regulate nerve, the specific nutrition material in the time of also can making intestinal dysfunction.
3, have ACE inhibition, morphineation, immunological regulation, multiple biologically active such as anti-oxidant, can stimulate the body lymphopoiesis, strengthen macrophage phagocytic function, improve the ability that body is resisted extraneous pathogenic infection, reduce the body incidence of disease etc.
4, the wheat gluten peptide is the wheat gluten enzymolysis product, can suppress the activity of ACE, the angiotensins that proangiotensin can not be transformed into can make blood pressure to raise, thereby physiology bring high blood pressure down, and normal arterial pressure is not reinstated.
Described kudzu-vine root powder (the Latin literary fame:
Radix Puerariae), its effective ingredient is a Puerarin, it has the blood pressure of adjusting, blood sugar, blood fat, reduces intraocular pressure, the protection brain cell; the protection retina suppresses platelet aggregation, and is anti-oxidant, myocardial preservation, anti-arrhythmia; diuresis, anti-inflammatory suppresses tumor cell proliferation, increases effects such as bone density.
Described soybean protein isolate, it has regulates blood fat, improves osteoporosis, suppresses effect such as blood pressure.
Described spirulina (the Latin literary fame:
Spirulina), it have improve immunity, regulate the body different physiological roles, enhance metabolism, anti-ageing, anticoagulation, fatigue-resisting function.Described soybean lecithin is a kind of mixed phosphatide, it is by phosphatid ylcholine (lecithin, be called for short PC, high-grade is PPC), phosphatidyl-ethanolamine (cephalin, abbreviation PE), phosphatidylinositols (lipositol, be called for short PI), phosphatidyl silk amino acid (silk amino acid phosphatide is called for short PS) etc. becomes to be grouped into, wherein most typical is first three kind.
Lecithin has the prevention fatty liver, reduces serum cholesterol content, prevents cirrhosis; Regulate diabetic's blood sugar concentration; Promote blood circulation, improve serum lipids, remove peroxide, make cholesterol and the reduction of neutral fat content in the blood; Slow down the process that is losing one's memory, effects such as prevention or postponement senile dementia.
Described isomalt, it has following effect:
1, is fit to diabetic and eats, can not cause that blood sugar and insulin rise.
2, the non-carious tooth that causes, intraoral streptococcus mutans can not decompose utilization, does not produce acid and glucan, can not cause decayed tooth, is particularly suitable for children and eats.
3, the hydrolysis rate of isomaltoketose is slow than sucrose, and infiltration rate can not cause the fluctuation of blood sugar level and plasma insulin level, so isomaltoketose can be used as diabetes patient's sweet taste material than slow many of sucrose.
4, isomalt is a kind of good Bifidobacterium MF, though isomalt can not be utilized by the enzyme of human body and most microorganisms system, but can be by the utilization that Bifidobacterium is decomposed in the human body intestinal canal, promote the growth and breeding of Bifidobacterium, keep the microecological balance of enteron aisle, help the health of human body.
Xylo-oligosaccharide (xylooligosaccharide) claims wood oligose again, is by the functional polymerization sugar of 2-7 wood sugar molecule with β-1,4 glycosidic bond be combined into.It can optionally promote the proliferation activity of intestinal bifidobacteria, and its bifidobacterium factor functional is 10-20 a times of other polymerization carbohydrate.Xylo-oligosaccharide has following characteristic:
1, xylo-oligosaccharide is difficult to the human consumption enzyme and decomposes
Expert's digestion experiment shows: various digestive juices nearly all can not decompose xylo-oligosaccharide, its energy value is almost nil, neither influence blood sugar concentration, do not increase insulin level in the blood sugar yet, and can not form fat deposition, so diabetes patient, adiposis patient and hypoglycemosis can relievedly eat per capita.
2, acid, Heat stability is good, difficult fermentation
Compare with other compound sugar, the outstanding feature of xylo-oligosaccharide is that stability is very good.Even (PH=2.5-7) is heated to 100 ℃ and also do not decompose substantially under acid condition, therefore can not cause the reduction of Bifidobacterium proliferation activity.
Xylo-oligosaccharide both can reach and prevent to suffer from diarrhoea, prevent constipation, and the protection liver function reduces the toxic metabolite product and forms, and has significantly reduced the burden effect that liver divides toxolysin; Simultaneously can also play the reduction serum cholesterol, bring high blood pressure down, can strengthen immunity of organisms, effect such as anticancer grade.
Microcrystalline cellulose and dolomol mainly are as excipient.
Above raw material all can be bought from the market and obtain, and need not special preparation.
Raw material isomalt of the present invention can substitute with xylo-oligosaccharide.The bifidobacterium factor functional of xylo-oligosaccharide is stronger 10 ~ 15 times than isomalt, is good sweetener for diabetic, the high crowd of blood sugar.
Polypeptide food can adopt conventional method to be prepared into tablet, capsule or pulvis.
Polypeptide food content of peptides of the present invention is more than 7.5%.Polypeptide food of the present invention meets the related request of state food.
The preparation method of food of the present invention is: after getting raw material in proportion by foregoing prescription earlier it is fully pulverized mixing, stirs, sterilizing, pour into capsule with conventional method then and make capsule, adopt conventional method to make tablet, or adopt conventional method to be prepared into pulvis.
Adopt the assay method of content of peptides among the present invention:
Principle: protein is easily precipitated under acid condition, and the polypeptide of lower molecular weight is that acid-soluble protein matter dissolves in trichloroacetic acid (TCA) solution (comprising polypeptide and free amino acid).Sample is after acidifying, and the sour molten protein content in the filtrate deducts the content that free aminoacid content is polypeptide.
The concrete analysis step is:
1, sour molten protein content determination
Get the 1g sample, the TCA solution 5ml of adding 15% mixes, and leaves standstill 10min, all move into solution in the centrifuge tube, 4000 rev/mins, centrifugal 10min gets whole supernatants, pressing the method for GB/T5009.5-2003 regulation measures, the protein conversion coefficient is 6.25, and assay loss on drying is per sample converted and is butt.Getting sour molten Protein content is P1.
2, free aminoacid content is measured
Get the 1g sample, add 15% TCA solution 5ml, mix, leave standstill 10min, solution is all moved in the centrifuge tube, 4000 rev/mins, centrifugal 10min gets whole supernatants, presses the method for GB/T5009.124-2003 regulation and measures.Getting free aminoacid content is P2.
3, the result calculates:
The mensuration content that the content P of polypeptide equals acid-soluble protein matter deducts the mensuration content of free amino acid, that is: P=P1-P2.
Advantage of the present invention:
1, raw material of the present invention all be health ministry approval be food be again the article or the new resource food of medicine, nutritive value is abundant, belongs to natural food; Through employing rational proportion to be prepared into polypeptide food, both kept the nutritive value of raw material, played the effect of preventing and curing diseases simultaneously, eating is of value to health, has enriched domestic and international polypeptide food kind simultaneously.
2, the suitable suitable crowd's scope of polypeptide food of the present invention is wide, the equal edibilities of special population such as hypertension, high fat of blood, diabetes.Raw material has added active ground dragon protein can play the adjusting thrombus, and stabilizing blood pressure is prevented and treated cranial vascular disease thereby reach, control blood pressure, lipids contents; The wheat oligopeptide that adds can play adjusting blood sugar, improves diabetic symptom, the effect that brings high blood pressure down; Soybean lecithin can provide lecithin, plays the effect of balance insulin secretion; Simultaneously with isomalt or xylo-oligosaccharide place of glucose and maltodextrin as auxiliary material, its low heat energy value and can not directly being digested and assimilated by human body is suitable as diabetic's sweetener.
3, polypeptide food of the present invention is of value to absorption of human body, adds nutritious wheat oligopeptide, and it contains 19 seed amino acids, and is low to the stomach function, absorption function shortcoming or poor slightly crowd, and food of the present invention helps absorption of human body.
4, the present invention has the reduction blood fat, balancing blood pressure, and prevention fatty liver, diarrhea and constipation delay effects such as senile dementia.Kudzu-vine root powder, soybean lecithin, spirulina and the soybean protein isolate that adds all helps eliminating the rubbish that produces in the body, reduces blood fat, effects such as balancing blood pressure.
Specific embodiment
The present invention is described further below in conjunction with instantiation, but protection scope of the present invention is not limited to the scope that embodiment represents.
Embodiment 1:
Prescription: active earthworm protein 20 g, wheat oligopeptide 10g, kudzu-vine root powder 12g, soybean protein isolate 15g, spirulina 15g, soybean lecithin 10g, isomalt 10g, microcrystalline cellulose 5g, dolomol 3g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make tablet according to a conventional method, every 0.7g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 7.5% ~ 9.0%.
Embodiment 2:
Prescription: active earthworm protein 32 g, wheat oligopeptide 25g, kudzu-vine root powder 10g, soybean protein isolate 10g, spirulina 10g, soybean lecithin 5g, isomalt 5g, microcrystalline cellulose 2g, dolomol 1g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make tablet according to a conventional method, every 0.3g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 18.9% ~ 22.5%.
Embodiment 3:
Prescription: active earthworm protein 21 g, wheat oligopeptide 13g, kudzu-vine root powder 25g, soybean protein isolate 11g, spirulina 12g, soybean lecithin 7g, isomalt 6g, microcrystalline cellulose 4g, dolomol 1g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make tablet according to a conventional method, every 0.5g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 9.8% ~ 11.7%.
Embodiment 4:
Prescription: active earthworm protein 23 g, wheat oligopeptide 15g, kudzu-vine root powder 13g, soybean protein isolate 15g, spirulina 12g, soybean lecithin 7g, isomalt 8g, microcrystalline cellulose 5g, dolomol 2g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make tablet according to a conventional method, every 1.0g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 11.3% ~ 13.7%.
Embodiment 5:
Prescription: active earthworm protein 25 g, wheat oligopeptide 20g, kudzu-vine root powder 12g, soybean protein isolate 11g, spirulina 15g, soybean lecithin 6g, isomalt 5g, microcrystalline cellulose 3g, dolomol 3g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make tablet according to a conventional method, every 0.2g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 15.2% ~ 18.4%.
Embodiment 6:
Prescription: active earthworm protein 20 g, wheat oligopeptide 22g, kudzu-vine root powder 12g, soybean protein isolate 13g, spirulina 11g, soybean lecithin 10g, isomalt 8g, microcrystalline cellulose 3g, dolomol 1g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make capsule according to a conventional method, every 0.25g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 16.5% ~ 20.1%.
Embodiment 7:
Prescription: active ground dragon protein 30g, wheat oligopeptide 11g, kudzu-vine root powder 13g, soybean protein isolate 11g, spirulina 12g, soybean lecithin 7g, isomalt 8g, microcrystalline cellulose 5g, dolomol 3g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make capsule according to a conventional method, every 0.4g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 8.2% ~ 10.1%.
Embodiment 8:
Prescription: active earthworm protein 24 g, wheat oligopeptide 18g, kudzu-vine root powder 15g, soybean protein isolate 12g, spirulina 13g, soybean lecithin 6g, isomalt 7g, microcrystalline cellulose 3g, dolomol 2g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make capsule according to a conventional method, every 0.15g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 13.5% ~ 16.4%.
Embodiment 9:
Prescription: active earthworm protein 21 g, wheat oligopeptide 23g, kudzu-vine root powder 11g, soybean protein isolate 12g, spirulina 12g, soybean lecithin 7g, isomalt 9g, microcrystalline cellulose 4g, dolomol 1g
Preparation method: pulverize after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make pulvis according to a conventional method, every bag of 10g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 17.3% ~ 21.1%.
Embodiment 10:
Prescription: active earthworm protein 31 g, wheat oligopeptide 14g, kudzu-vine root powder 12g, soybean protein isolate 13g, spirulina 13g, soybean lecithin 8g, isomalt 5g, microcrystalline cellulose 3g, dolomol 1g
Preparation method: pulverize after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, isomalt, microcrystalline cellulose and dolomol fully mixed, stir, make pulvis according to a conventional method, every bag of 15g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 10.5% ~ 12.6%.
Embodiment 11:
Prescription: active earthworm 4 protein 22 g, wheat oligopeptide 25g, kudzu-vine root powder 10g, soybean protein isolate 11g, spirulina 15g, soybean lecithin 6g, xylo-oligosaccharide 5g, microcrystalline cellulose 3g, dolomol 3g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, xylo-oligosaccharide, microcrystalline cellulose and dolomol fully mixed, stir, make tablet according to a conventional method, every 0.2g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 20.1% ~ 22.3%.
Embodiment 12:
Prescription: active earthworm protein 25 g, wheat oligopeptide 22g, kudzu-vine root powder 10g, soybean protein isolate 10g, spirulina 11g, soybean lecithin 10g, xylo-oligosaccharide 8g, microcrystalline cellulose 3g, dolomol 1g
Preparation method: after above-mentioned active ground dragon protein, wheat oligopeptide, kudzu-vine root powder, soybean protein isolate, spirulina, soybean lecithin, xylo-oligosaccharide, microcrystalline cellulose and dolomol fully mixed, stir, make capsule according to a conventional method, every 0.25g.
The polypeptide food that contains active ground dragon protein for preparing, its content of peptides is 19.5% ~ 21.3%.
Claims (5)
1. polypeptide food that contains active ground dragon protein, it is characterized in that: it comprises the raw material of following parts by weight:
Active earthworm protein 20～35 parts
10～25 parts of wheat oligopeptides
10～25 parts of kudzu-vine root powder
10～15 parts of soybean protein isolates
10～15 parts of spirulinas
5～10 parts of soybean lecithins
5～10 parts of isomalts
2～5 parts of microcrystalline celluloses
1～3 part of dolomol.
2. the polypeptide food that contains active ground dragon protein according to claim 1, it is characterized in that: it comprises the raw material of following parts by weight:
Active earthworm protein 25～35 parts
20～25 parts of wheat oligopeptides
10～15 parts of kudzu-vine root powder
10～13 parts of soybean protein isolates
10～15 parts of spirulinas
5～10 parts of soybean lecithins
5～10 parts of isomalts
2～5 parts of microcrystalline celluloses
1～3 part of dolomol.
3. the polypeptide food that contains active ground dragon protein according to claim 1 and 2 is characterized in that: described raw material isomalt can substitute with xylo-oligosaccharide.
4. the polypeptide food that contains active ground dragon protein according to claim 1 and 2, it is characterized in that: described polypeptide food is tablet, capsule or pulvis.
5. the polypeptide food that contains active ground dragon protein according to claim 1 and 2, it is characterized in that: the content of peptides of described polypeptide food is more than 7.5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310184111.8A CN103211150B (en) | 2013-05-17 | 2013-05-17 | Polypeptide food containing active earthworm protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310184111.8A CN103211150B (en) | 2013-05-17 | 2013-05-17 | Polypeptide food containing active earthworm protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103211150A true CN103211150A (en) | 2013-07-24 |
| CN103211150B CN103211150B (en) | 2014-10-29 |
Family
ID=48809595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310184111.8A Expired - Fee Related CN103211150B (en) | 2013-05-17 | 2013-05-17 | Polypeptide food containing active earthworm protein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103211150B (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104770729A (en) * | 2015-04-28 | 2015-07-15 | 天津民生生物工程有限公司 | Lumbricus protein compound tablets and manufacturing method thereof |
| CN104855845A (en) * | 2015-06-08 | 2015-08-26 | 周维官 | Natto nutritional health food |
| CN107149140A (en) * | 2017-05-17 | 2017-09-12 | 乳山寰海生物科技有限公司 | A kind of nutritious and healthy food containing ganoderma lucidum mycelium |
| CN108077941A (en) * | 2017-12-22 | 2018-05-29 | 广东正当年生物科技有限公司 | A kind of algae peptide combinations and preparation method and application |
| CN108142929A (en) * | 2017-12-26 | 2018-06-12 | 周其燕 | A kind of food of health-nutrition containing silkworm chrysalis |
| CN108770882A (en) * | 2018-06-06 | 2018-11-09 | 广西宾德利生物科技有限公司 | Earthworm microalgae small-molecular peptides and the preparation method and application thereof |
| CN110051005A (en) * | 2019-05-27 | 2019-07-26 | 朱国强 | A kind of composite functional food of thrombus blood lipid and preparation method thereof |
| CN110477396A (en) * | 2019-09-11 | 2019-11-22 | 广西优未康生物科技有限公司 | A kind of polypeptide food containing bamboo-leaves flavones |
| CN114028535A (en) * | 2021-12-16 | 2022-02-11 | 重庆希尔安药业有限公司 | Selenium-rich earthworm protein composition for promoting fracture healing and preparation method thereof |
| CN114642236A (en) * | 2022-03-23 | 2022-06-21 | 广州高人汇生物科技有限公司 | Chlorella natto tablet candy capable of assisting in lowering blood pressure |
| CN115025126A (en) * | 2022-06-23 | 2022-09-09 | 广元市中医医院 | Application of earthworm in preparing medicament for preventing and/or treating fatty liver |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101971988A (en) * | 2010-10-11 | 2011-02-16 | 孙羽蒙 | Prescription for treating female climacteric syndrome |
| CN102068460A (en) * | 2009-11-24 | 2011-05-25 | 上海中医药大学 | Earthworm protein-containing buccal instant preparation, preparation method and application thereof |
| CN102885301A (en) * | 2012-09-19 | 2013-01-23 | 北京同仁堂健康药业股份有限公司 | Composition for enhancing immunity and preparation method thereof |
| CN102972673A (en) * | 2012-11-29 | 2013-03-20 | 广州纽健生物科技有限公司 | Nutritional food for improving intestinal dysfunction |
-
2013
- 2013-05-17 CN CN201310184111.8A patent/CN103211150B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102068460A (en) * | 2009-11-24 | 2011-05-25 | 上海中医药大学 | Earthworm protein-containing buccal instant preparation, preparation method and application thereof |
| CN101971988A (en) * | 2010-10-11 | 2011-02-16 | 孙羽蒙 | Prescription for treating female climacteric syndrome |
| CN102885301A (en) * | 2012-09-19 | 2013-01-23 | 北京同仁堂健康药业股份有限公司 | Composition for enhancing immunity and preparation method thereof |
| CN102972673A (en) * | 2012-11-29 | 2013-03-20 | 广州纽健生物科技有限公司 | Nutritional food for improving intestinal dysfunction |
Non-Patent Citations (1)
| Title |
|---|
| 朱婧，等: "蛋白质类新资源食品比较研究.", 《中国卫生监督杂志》, vol. 18, no. 1, 31 January 2011 (2011-01-31), pages 55 - 59 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104770729A (en) * | 2015-04-28 | 2015-07-15 | 天津民生生物工程有限公司 | Lumbricus protein compound tablets and manufacturing method thereof |
| CN104855845A (en) * | 2015-06-08 | 2015-08-26 | 周维官 | Natto nutritional health food |
| CN107149140A (en) * | 2017-05-17 | 2017-09-12 | 乳山寰海生物科技有限公司 | A kind of nutritious and healthy food containing ganoderma lucidum mycelium |
| CN108077941A (en) * | 2017-12-22 | 2018-05-29 | 广东正当年生物科技有限公司 | A kind of algae peptide combinations and preparation method and application |
| CN108142929A (en) * | 2017-12-26 | 2018-06-12 | 周其燕 | A kind of food of health-nutrition containing silkworm chrysalis |
| CN108770882A (en) * | 2018-06-06 | 2018-11-09 | 广西宾德利生物科技有限公司 | Earthworm microalgae small-molecular peptides and the preparation method and application thereof |
| CN110051005A (en) * | 2019-05-27 | 2019-07-26 | 朱国强 | A kind of composite functional food of thrombus blood lipid and preparation method thereof |
| CN110477396A (en) * | 2019-09-11 | 2019-11-22 | 广西优未康生物科技有限公司 | A kind of polypeptide food containing bamboo-leaves flavones |
| CN114028535A (en) * | 2021-12-16 | 2022-02-11 | 重庆希尔安药业有限公司 | Selenium-rich earthworm protein composition for promoting fracture healing and preparation method thereof |
| CN114028535B (en) * | 2021-12-16 | 2023-12-15 | 重庆希尔安药业有限公司 | Selenium-enriched earthworm protein composition for promoting fracture healing and preparation method thereof |
| CN114642236A (en) * | 2022-03-23 | 2022-06-21 | 广州高人汇生物科技有限公司 | Chlorella natto tablet candy capable of assisting in lowering blood pressure |
| CN115025126A (en) * | 2022-06-23 | 2022-09-09 | 广元市中医医院 | Application of earthworm in preparing medicament for preventing and/or treating fatty liver |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103211150B (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103211150B (en) | Polypeptide food containing active earthworm protein | |
| CN102823800B (en) | Polypeptide nutritional health-care food containing marine fish oligopeptides | |
| CN102524872B (en) | Ginseng peptide amino acid drink | |
| CN105028868A (en) | Black garlic, black onion and black soybean peptide chewable tablet and preparation method thereof | |
| CN102783636A (en) | Food nutrition supplement for prophylaxis and treatment of diabetes and application thereof | |
| CN104839664A (en) | Medical formula food for osteoporosis | |
| CN102178183A (en) | Five-bean comprehensive nutritional food | |
| CN104921099A (en) | Diabetes specific complex oligopeptide food and manufacturing method and application thereof | |
| CN104855975A (en) | Non-total-nutrient formula food for sarcopenia syndrome | |
| CN1315418C (en) | Instant drinking powder contg. black-fungus, oatmeal and spirulina, and its prepn. method | |
| CN107691794A (en) | A kind of Papillon pup dog food and preparation method thereof | |
| CN104996992A (en) | Medical formula food for muscle attenuation syndromes | |
| CN107821713A (en) | Collagen mineral complex pressed candy | |
| CN105878397A (en) | Composition capable of regulating transportation stress of cattle and sheep | |
| CN107149140A (en) | A kind of nutritious and healthy food containing ganoderma lucidum mycelium | |
| CN104172168A (en) | Convenient food capable of alleviating atherosclerosis | |
| CN101856369A (en) | Stachyose tablets for calcium supplementation and intestinal micro-ecological regulation | |
| CN109170916A (en) | One kind keeps fit and healthy food compositions and preparation method thereof | |
| CN105707681A (en) | Supermicro black fungus nutrient porridge with blood sugar reducing function and making method thereof | |
| CN1101700C (en) | Polypeptide oral liquor | |
| CN104757689A (en) | Solid beverage with pine pollen, taurine and vitamins, and preparation method of the solid beverage | |
| CN107136490A (en) | A kind of peptide Chinese caterpillar fungus health product | |
| CN101224005B (en) | Nutrient tablet possessing whole nutrient supplementing efficacy and producing method thereof | |
| KR20110136938A (en) | Pill with sea cucumber and manufacturing process thereof | |
| CN111227229A (en) | Plant source nutrition powder and preparation method and edible method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180619 Address after: 530012 No. 49 National Road, Qingxiu District, Nanning, the Guangxi Zhuang Autonomous Region, 1602, B complex, Guangxi National Palace commercial center. Patentee after: Nanning city Renqin sea Biotechnology Co. Ltd. Address before: 530219 104 Jinsha Road, LIANG Qing District, Nanning, the Guangxi Zhuang Autonomous Region Patentee before: Hu Kai |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141029 Termination date: 20190517 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |